NewsBenzinga암젠·아스트라제네카, 난치성 폐암 치료제 병용요법에서 유망한 생존율 결과 나타내 암젠·아스트라제네카, 난치성 폐암 치료제 병용요법에서 유망한 생존율 결과 나타내 Benzinga 2026.10.26 13:23 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report